Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Ban2401

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401
    BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401

    20 May 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bioarctic-receives-meur-15-milestone-payment-from-eisai-for-start-of-ban2401-confirmatory-phase-3-study-in-early-alzheimers-disease-300853227.html

    PR NEWSWIRE
    20 May 2019
    Share Share
    BioArctic: Eisai Announces Timelines for Single Confirmatory Ph3 Study BAN2401
    BioArctic: Eisai Announces Timelines for Single Confirmatory Ph3 Study BAN2401

    07 Mar 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bioarctic-eisai-announces-timelines-for-the-single-confirmatory-phase-3-study-with-ban2401-in-warly-alzheimers-disease-300808348.html

    PR NEWSWIRE
    07 Mar 2019
    Share Share
    Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022
    Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

    07 Mar 2019

    // Phil Taylor PMLIVE

    http://www.pmlive.com/pharma_news/biogen,_eisai_cue_up_ban2401_readout_in_alzheimers_in_2022_1280698

    Phil Taylor PMLIVE
    07 Mar 2019
    Share Share